evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

304 questions · 309 findings · 37 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 80 · 25.9%GRADE not reported 8 · 2.6%Very low 88 · 28.5%Low 75 · 24.3%Moderate 54 · 17.5%High 4 · 1.3%

Intervention not reported

IPC –not daily drainage (2 RCTs, 160 participants) VAS scores at 42 days and 180 days · adults with malignant pleural effusion Interventions: talc poudrage, bleomycin, IPC – not daily drainage, doxycycline, placebo Comparator…
1 finding from 1 review

Infliximab 5 mg/kg vs infliximab 10 mg/kg

Clinical remission defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with infliximab 10 mg/kg (very low certainty).

1 finding from 1 review

Infliximab 5 mg/kg vs infliximab 10 mg/kg

Clinical response defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with infliximab 10 mg/kg (very low certainty).

1 finding from 1 review

Infliximab 5–10 mg/kg vs placebo

Clinical remission defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5–10 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with placebo (very low certainty).

1 finding from 1 review

Infliximab 5–10 mg/kg vs placebo

Clinical response defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5–10 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with placebo (very low certainty).

1 finding from 1 review